文献速递生殖医学

多囊卵巢综合征女性中吻素与神经激肽B在调节促性腺激素分泌中的相互作用

Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2020-01-01

研究在多囊卵巢综合征(PCOS)女性中给予神经激肽3受体拮抗剂(NK3Ra)MLE4901 40 mg每日两次口服7天,与未治疗者比较,并交叉进行吻素-10或溶媒输注。NK3Ra降低LH分泌、LH脉冲频率和FSH分泌,吻素-10刺激LH的反应在NK3Ra后保留,但与雌二醇的正相关消失。

要点

  • NK3Ra治疗7天降低PCOS女性LH分泌、LH脉冲频率和FSH分泌。
  • 无NK3Ra预处理时吻素-10增加LH分泌,且与雌二醇浓度正相关。
  • NK3Ra后吻素-10仍刺激LH分泌,但与雌二醇的正相关消失。

核心结论

  • 数据表明在PCOS中NKB和吻素交互调节GnRH/LH分泌,且NKB系统介导雌激素反馈的某些方面。

研究设计与样本

  • NK3Ra MLE4901 40 mg口服每日两次给予PCOS女性7天(n=8),对照为未治疗(n=7);在NK3Ra最后一天或未治疗者等效日,随机接受7小时吻素-10(4 µg/kg/h 静脉)或溶媒输注,并在后续周期交叉重复。
  • 受试者为PCOS女性,在临床研究机构进行研究;在NK3Ra给药前后测量生殖激素;在NK3Ra最后一天或未治疗者等效周期日,所有女性进行8小时频繁采血以分析LH脉冲分泌。

主要发现

  • NK3Ra降低LH分泌(4.0 ± 0.4 vs 6.5 ± 0.8 IU/l,P < 0.05)和脉冲频率(0.5 ± 0.1 vs 0.8 ± 0.1 脉冲/h,P < 0.05);FSH分泌也降低(2.0 ± 0.3 vs 2.5 ± 0.4 IU/l,P < 0.05)。
  • 无NK3Ra预处理时,吻素-10增加LH分泌(5.2 ± 0.5 至 7.8 ± 1.0 IU/L,P < 0.05),与雌二醇浓度呈正相关(r2 = 0.59,P < 0.05)。
  • NK3Ra给药后,LH对吻素-10的反应保留(溶媒 3.5 ± 0.3 vs 吻素-10 9.0 ± 2.2 IU/l,P < 0.05),但与雌二醇浓度的正相关消失(NK3Ra后 r2 = 0.07,ns)。
  • NK3Ra治疗后吻素-10增加FSH分泌,而无NK3Ra治疗时未增加。

局限性

  • 研究未探索NK3R拮抗作用的剂量关系。
  • 由于受试者数量少,未研究肥胖或PCOS表型变异性其他方面的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the role of the hypothalamic neuropeptide neurokinin B (NKB) and its interaction with kisspeptin on GnRH/LH secretion in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Administration of neurokinin 3 receptor antagonist (NK3Ra) for 7 days reduced LH and FSH secretion and LH pulse frequency in women with PCOS, whilst the stimulatory LH response to kisspeptin-10 was maintained. WHAT IS KNOWN ALREADY: PCOS is characterized by abnormal GnRH/LH secretion. NKB and kisspeptin are master regulators of GnRH/LH secretion, but their role in PCOS is unclear. STUDY DESIGN, SIZE, DURATION: The NK3Ra MLE4901, 40 mg orally twice a day, was administered to women with PCOS for 7 days (n = 8) (vs no treatment, n = 7). On the last day of NK3Ra administration or the equivalent day in those not treated, women were randomized to 7-h kisspeptin-10 (4 µg/kg/h i.v.) or vehicle infusion. This was repeated with the alternate infusion in a subsequent cycle. PARTICIPANTS/MATERIALS, SETTING, METHODS: Subjects were women with PCOS, studied in a Clinical Research Facility. Reproductive hormones were measured before and after NK3Ra administration. On the last day of NK3Ra administration (or the equivalent cycle day in untreated women), all women attended for an 8-h frequent blood sampling to allow analysis of the pulsatile LH secretion. MAIN RESULTS AND THE ROLE OF CHANCE: NK3Ra reduced LH secretion (4.0 ± 0.4 vs 6.5 ± 0.8 IU/l, P < 0.05) and pulse frequency (0.5 ± 0.1 vs 0.8 ± 0.1 pulses/h, P < 0.05); FSH secretion was also reduced (2.0 ± 0.3 vs 2.5 ± 0.4 IU/l, P < 0.05). Without NK3Ra pre-treatment, kisspeptin-10 increased LH secretion (5.2 ± 0.5 to 7.8 ± 1.0 IU/L, P < 0.05), with a positive relationship to oestradiol concentrations (r2 = 0.59, P < 0.05). After NK3Ra administration, the LH response to kisspeptin-10 was preserved (vehicle 3.5 ± 0.3 vs 9.0 ± 2.2 IU/l with kisspeptin-10, P < 0.05), but the positive correlation with oestradiol concentrations was abolished (r2 = 0.07, ns. after NK3Ra). FSH secretion was increased by kisspeptin-10 after NK3Ra treatment, but not without NK3Ra treatment. LIMITATIONS, REASONS FOR CAUTION: The study did not explore the dose relationship of the effect of NK3R antagonism. The impact of obesity or other aspects of the variability of the PCOS phenotype was not studied due to the small number of subjects. WIDER IMPLICATIONS OF THE FINDINGS: These data demonstrate the interactive regulation of GnRH/LH secretion by NKB and kisspeptin in PCOS, and that the NKB system mediates aspects of oestrogenic feedback. STUDY FUNDING/COMPETING INTEREST(S): Wellcome Trust through Scottish Translational Medicine and Therapeutics Initiative (102419/Z/13/A) and MRC grants (G0701682 to R.P.M. and R.A.A.) and MR/N022556/1 to the MRC Centre for Reproductive Health. This work was performed within the Edinburgh Clinical Research Facility. J.T.G. has undertaken consultancy work for AstraZeneca and Takeda Pharmaceuticals and is an employee of Boehringer Ingelheim. R.P.M. has consulted for Ogeda and was CEO of Peptocrine. R.A.A. has undertaken consultancy work for Merck, Ferring, NeRRe Therapeutics and Sojournix Inc. J.D.V. and K.S. have nothing to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Skorupskaite K, George JT, Veldhuis JD, et al. Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome. Hum Reprod. 2020. PMID: 32510130. doi:10.1093/humrep/deaa104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。